LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, has been named the “Late Stage Leader” Buzz of BIO winner. As a winner of this award – which recognizes innovative companies that have raised more than $25 million as of July 1, 2016 – Quanterix will also be presenting at the 2016 BIO Investor Forum, taking place October 18-19 in San Francisco.
Quanterix was recognized by Bio for its innovative, research-backed Simoa technology and impressive company growth. Included in over 100 peer-reviewed publications, Quanterix’ Simoa technology is providing researchers with a way to detect and diagnose disease earlier and more accurately than possible today through its digital biomarker analysis capabilities. In addition to raising $46M in Series D financing this year alone, the company has seen a 300 percent increase in revenue and a 76.6 percent increase in customers from 2014 to 2015.
“We are honored to be recognized by such a prestigious organization whose mission to transform how we heal, fuel and feed the world directly aligns with our overarching goal to turn today’s unproductive ‘sick care’ into true, precision medicine,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “We look forward to joining the impressive roster of speakers at the upcoming BIO Investor Forum to help further spread our message and present the impact Simoa will have on the future of healthcare.”
The Buzz of BIO award is associated with Bio, the largest global trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event attracts over 900 private equity and public investors, research analysts, and industry executives focused on investment and business development opportunities in the life sciences industry.
Kevin will be speaking at the Forum on Tuesday, October 18th at 2:30pm PT on Quanterix’ business objectives, investment goals and the Simoa technology. For those not attending the forum, the presentation can be viewed live through the following link: https://www.veracast.com/webcasts/bio/investorforum2016/02115398665.cfm.
To learn more about the BIO Investor Forum, please visit: https://www.bio.org/events/bio-investor-forum/about.
Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.